Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify in Children and Adolescents With Bipolar Disorder
NCT00221416Phase 3Completed
- Sponsor
- University of Cincinnati
- Start
- Jun 2005
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in bipolar I disorder, sponsored by University of Cincinnati. Primary endpoints: Young Mania Rating Scale at 6 weeks and Clinical Global Impression at 6 weeks. Started Jun 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00221416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221416.